Edition:
United States

Bristol-Myers Squibb Co (BMY.N)

BMY.N on New York Stock Exchange

60.80USD
4:00pm EDT
Change (% chg)

$-0.68 (-1.11%)
Prev Close
$61.48
Open
$61.54
Day's High
$62.21
Day's Low
$60.60
Volume
1,266,649
Avg. Vol
1,678,233
52-wk High
$70.04
52-wk Low
$49.97

Select another date:

Wed, Sep 12 2018

Photo

Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

CORRECTED-Bristol-Myers plaque psoriasis drug shows promise in mid-stage trial

Sept 12 Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial.

FDA approves Bristol-Myers' Opdivo for small cell lung cancer

Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.

FDA approves Bristol-Myers' Opdivo for small cell lung cancer

Aug 17 Bristol-Myers Squibb Co said on Friday the U.S. Food and Drug Administration approved its treatment, Opdivo, for patients whose lung cancer had progressed even after undergoing chemotherapy and at least one other therapy.

Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

UPDATE 2-Bristol-Myers cancer ruling hits shares after strong earnings

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday said European regulators plan to recommend against approving its immunotherapy combination as an initial treatment for kidney cancer, sending shares lower even after the U.S. drugmaker reported better-than-expected quarterly profit and raised its full-year forecast.

Bristol-Myers to get negative CHMP opinion on renal cancer drugs

NEW YORK Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.

Bristol-Myers to get negative CHMP opinion on renal cancer drugs

NEW YORK, July 26 Bristol-Myers Squibb Co said on Thursday it was told by European regulators that they will recommend against approving the company's drugs Opdivo and Yervoy to treat first-line renal cancer.

Bristol-Myers Q2 earnings rise, full-year forecast up on strong sales

NEW YORK, July 26 Bristol-Myers Squibb Co on Thursday posted better-than-expected second-quarter earnings and raised its full-year forecast on strong sales from its blockbuster cancer drug Opdivo and blood thinner Eliquis.

Exclusive: BMS hires banks for 1 billion euro-plus sale of French OTC drug unit - sources

LONDON U.S. pharmaceuticals giant Bristol-Myers Squibb has hired two banks to find a buyer for its French over-the-counter (OTC) drugs business, which could be valued at more than 1 billion euros in a potential deal, sources familiar with the matter told Reuters.

Select another date: